| Source: |
| Type: |
| Toxicity |
| - | Study, | AD, | NA |
| 2885- | HNK, | Honokiol: a novel natural agent for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2871- | HNK, | Antihyperalgesic Properties of Honokiol in Inflammatory Pain Models by Targeting of NF-κB and Nrf2 Signaling |
| - | in-vivo, | Nor, | NA |
| 2865- | HNK, | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
| - | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
| 2891- | HNK, | Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs |
| - | Review, | Var, | NA |
| 2895- | HNK, | Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity |
| - | in-vitro, | Lung, | PC9 |
| 2079- | HNK, | Honokiol Microemulsion Causes Stage-Dependent Toxicity Via Dual Roles in Oxidation-Reduction and Apoptosis through FoxO Signaling Pathway |
| - | in-vitro, | Nor, | PC12 |
| 7624- | HPT, | Chemo, | A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer |
| - | Trial, | Cerv, | NA |
| 7599- | HPT, | Rad, | Recent development on hyperthermia: An effective cotreatment improving radiotherapy outcome |
| - | Review, | Var, | NA |
| 7598- | HPT, | Rad, | Chemo, | The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials |
| - | Review, | Var, | NA |
| 7622- | HPT, | A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers |
| - | Review, | Var, | NA |
| 7627- | HPT, | Rad, | Local control rate after the combination of re-irradiation and hyperthermia for irresectable recurrent breast cancer: Results in 248 patients |
| - | Trial, | BC, | NA |
| 7542- | HT, | Hydroxytyrosol Induces Apoptosis and Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B | - | in-vitro, | Nor, | RWPE-1 |
| 7524- | HT, | The Pharmaceutical Formulation Plays a Pivotal Role in Hydroxytyrosol Pharmacokinetics |
| - | Trial, | Nor, | NA |
| 4639- | HT, | Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 7565- | HYP, | Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review |
| - | Review, | AD, | NA |
| 7560- | HYP, | Hyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
| 7602- | I3C, | Dose-ranging study of indole-3-carbinol for breast cancer prevention |
| - | Trial, | BC, | NA |
| 7583- | I3C, | Indole-3-carbinol prevented tumor progression and potentiated PD1ab therapy by upregulating PTEN in colorectal cancer |
| - | vitro+vivo, | CRC, | NA |
| 7589- | I3C, | Indole-3-carbinol inhibits cell proliferation and induces apoptosis in Hep-2 laryngeal cancer cells |
| - | vitro+vivo, | Laryn, | HEp2 |
| 7801- | IBC, | Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter |
| - | in-vitro, | CRC, | HT-29 |
| 7578- | IMA, | Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia |
| - | Trial, | CML, | NA |
| 7616- | Ins, | A phase I study of myo-inositol for lung cancer chemoprevention |
| - | Trial, | Nor, | NA |
| 7633- | Ins, | Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use |
| - | Trial, | Nor, | NA |
| 7637- | Ins, | Investigating the mechanism of inositol against paclitaxel chemoresistance on triple-negative breast cancer by using 7T multiparametric MRI and mitochondrial changes |
| - | vitro+vivo, | BC, | 4T1 |
| 7631- | Ins, | IP6, | Broad Spectrum Anticancer Activity of Myo-Inositol and Inositol Hexakisphosphate |
| - | Review, | Var, | NA |
| 7662- | IP, | Digestive tolerance of inulin-type fructans: a double-blind, placebo-controlled, cross-over, dose-ranging, randomized study in healthy volunteers |
| - | Trial, | Nor, | NA |
| 7712- | IP6, | Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice |
| - | in-vivo, | Pca, | NA |
| 7722- | IP6, | Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic |
| - | Review, | Var, | NA |
| 7723- | IP6, | Prostate cancer and inositol hexaphosphate: efficacy and mechanisms |
| - | Review, | Pca, | NA |
| 7690- | IP6, | Ins, | Inositol Hexaphosphate (IP6) and Colon Cancer: From Concepts and First Experiments to Clinical Application |
| - | Review, | Colon, | NA |
| 7699- | IP6, | IP6: From Seeds to Science—A Natural Compound’s Path to Clinical Promise |
| - | Review, | Var, | NA |
| 7756- | ISL, | Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway |
| - | vitro+vivo, | BC, | MCF7 | - | vitro+vivo, | BC, | MDA-MB-231 |
| 7758- | ISL, | Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic implications |
| - | Review, | Ovarian, | NA |
| 7765- | ISL, | Isoliquiritigenin as a modulator of the Nrf2 signaling pathway: potential therapeutic implications |
| - | Review, | Var, | NA |
| 7739- | isoFl, | Soy, red clover, and isoflavones and breast cancer: a systematic review |
| - | Review, | BC, | NA |
| 7735- | isoFl, | Soy Isoflavones in Integrative Oncology: Increased Efficacy and Decreased Toxicity of Cancer Therapy |
| - | Review, | Var, | NA |
| 7854- | isoO, | Isoorientin induces apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cancer cells |
| - | in-vitro, | Liver, | HepG2 |
| 7881- | isoO, | Effects of Natural Flavonoid Isoorientin on Growth Performance and Gut Microbiota of Mice |
| - | in-vivo, | Nor, | NA |
| 7880- | isoO, | Inhibition of ROS-mediated activation Src-MAPK/AKT signaling by orientin alleviates H2O2-induced apoptosis in PC12 cells |
| - | in-vitro, | Nor, | PC12 |
| 7866- | isoO, | Orientin and Cancer Suppression: Molecular Mechanisms and Synergistic Effects |
| - | Review, | Var, | NA |
| 7846- | ISQ, | Ninety-day toxicity and single-dose toxicokinetics study of alpha-glycosyl isoquercitrin in Sprague-Dawley rats |
| - | in-vivo, | Nor, | NA |
| 7848- | ISQ, | Review of anticancer mechanisms of isoquercitin |
| - | Review, | Var, | NA |
| 9232- | ITCs, | SFN, | The role of isothiocyanate-rich plants and supplements in neuropsychiatric disorders: a review and update |
| - | Review, | AD, | NA |
| 9173- | ITCs, | SFN, | Dietary isothiocyanates and anticancer agents: exploring synergism for improved cancer management |
| - | Review, | Var, | NA |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 7996- | itraC, | Itraconazole in the Treatment of Aberrantly Active Hedgehog and/or PI3K Recurrent Ovarian Cancer |
| - | Trial, | Ovarian, | NA |
| 8009- | itraC, | Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways |
| - | vitro+vivo, | Melanoma, | SK-MEL-28 | - | vitro+vivo, | Melanoma, | A375 |
| 7984- | itraC, | The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells |
| - | in-vitro, | Nor, | NA |
| 7991- | itraC, | A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low-Risk Basal Cell Carcinoma |
| - | Trial, | BCC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1025 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid